Meningococcal vaccine groups A C Y W-135 conjugate - Yuxi Walvax Biotechnology

Drug Profile

Meningococcal vaccine groups A C Y W-135 conjugate - Yuxi Walvax Biotechnology

Alternative Names: Group ACYW135 meningococcal polysaccharide vaccine - Walvax; Ingovax ACWY

Latest Information Update: 07 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Walvax Biotechnology
  • Developer Incepta Vaccine; Walvax Biotechnology
  • Class Meningococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Meningococcal infections

Most Recent Events

  • 27 Aug 2017 International Centre for Diarrhoeal Disease Research, Bangladesh and Incepta Vaccine plan a phase II/III trial for Meningococcal infections (Prevention, In adults) in Bangladesh (SC) (NCT03263403)
  • 20 Aug 2017 Launched for Meningococcal infections (In adolescents, In adults, In children, Prevention) in Bangladesh (SC) before August 2017 (Incepta Vaccine website)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top